Comparative Analysis of P40 and 34betaE12. Immunohistochemistry in the Diagnosis of Prostate Lesions: Insights into Diagnostic Utility

Introduction: Prostate carcinoma remains one of the commonly diagnosed cancers and a leading cause of morbidity and mortality worldwide. The diagnostic challenge in distinguishing benign and malignant prostate lesions remains significant, especially in small biopsies. Immunohistochemistry(IHC) serves as a valuable adjunct tool in the diagnosis and management of prostate malignancies. This study aims to evaluate the utility of P40 expression in the diagnosis of prostate lesions and to compare with the immunohistochemical expression of 34betaE12 in benign, premalignant and malignant lesions of the prostate. Materials & methods: This investigation was done at the Sree Balaji Medical College and Hospital, Department of Pathology,Chennai,India. Total 41 males with prostate specimens Prostatic specimens(biopsies and resections) satisfying inclusion and exclusion criteria were included in this cross-sectional research study.Initial sections weres tained with Hematoxylin and eosin stain followed by IHC staining with two markers, P40 and 34BetaE12.Data were analysed using the mean and standard deviation for quantitative variables, as well as frequency and percentage for categorical variables, for descriptive purposes. Statistical analysis was made with IBM SPSS 16.0 software and P value of <0.05 was considered significant. RESULTS: Of the 41 cases examined, the most prevalent pathology was a benign lesion(51.2%), followed by 41.5% malignant and 7.3% had premalignant lesions. All patients with benign lesions and pre-malignant lesions were positive and all malignant lesions were negative for P40 staining. There was statistically significant increase in P40 and 35betaE12 staining among patients with benign and pre- malignant lesions. Conclusion: Our findings suggest that immunohistochemical markers 34betaE12 and p40 have been found to be of value in differentiating benign and malignant lesions of the prostate thereby playing an important role in management of patient and therapeutic outcome.